-
BeiGene TIGIT monoclonal antibody BGB-A1217 injection was approved for clinical use
Time of Update: 2021-05-02
On April 9, 2021, the CDE official website showed that BeiGene TIGIT monoclonal antibody BGB-A1217 injection was approved for clinical use, and the indication is advanced solid tumors.
BGB-A1217 is a TIGIT monoclonal antibody developed by BeiGene.
-
2021 AACR: BeiGene Reveals Bazeran® for second/third-line treatment of advanced non-small cells
Time of Update: 2021-05-02
On April 13, 2021, Beijing time, BeiGene's self-developed anti-PD-1 antibody drug Bezean® (tislelizumab) compared with docetaxel for the second disease progression after platinum-based chemotherapy /Detailed data of the global phase III clinical trial (RATIONALE 303 study) in patients with third-line locally advanced or metastatic non-small cell lung cancer was disclosed at the 112th American Cancer Society Annual Meeting (AACR).
-
Hausen's ``Ametinib'' plans to be included in breakthrough therapy for the first-line treatment of NSCLC
Time of Update: 2021-05-02
On April 9, the indications for the first-line treatment of Epidermal Growth Factor Receptor (EGFR) sensitive mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) with Ametinib tablets by Hausen Pharmaceuticals was proposed by CDE as a breakthrough therapy.
-
Kangtai Bio-New Coronary Inactivated Vaccine Data: Neutralizing Antibody Is 2.65 Times Recovered
Time of Update: 2021-05-02
7. The clinical data of the new crown vaccine compiled by the medical team of Dongxing Securities shows that the antibody titer vaccine group/recovered multiple of them ranks first in China and fourth in the world.
-
In 4 months, the market value has evaporated by nearly 200 billion yuan.
Time of Update: 2021-05-02
Several major varieties of Hengrui Pharmaceuticals, such as docetaxel, oxaliplatin, atracurium cisbesilate, and iodixanol, are in the fifth batch of centralized procurement catalogs, with sales totaling more than 4 billion.
Hengrui's financial report shows that in recent years, R&D investment accounted for more than 17% of sales revenue.
-
Hengrui Pharmaceuticals Ivabradine Hydrogen Sulfate Sustained-Release Tablets Approved for Clinical Trial
Time of Update: 2021-05-02
On April 20, Hengrui Medicine issued an announcement stating that it had recently received approval from the State Food and Drug Administration to issue a "Drug Clinical Trial Approval Notice" for ivabradine hydrogen sulfate sustained-release tablets, and clinical trials will be launched in the near future.
-
For adult lupus nephritis, Hengrui Pharmaceutical's subsidiary SHR-1314 injection was approved for clinical use
Time of Update: 2021-05-02
Novartis' secukinumab (trade name Cosentyx) has been approved for listing in many countries and regions including the United States, Europe and Japan since 2015.
Eli Lilly’s ixekizumab (trade name Taltz) has been approved for listing in the United States, Europe, Japan and other countries and regions since 2016.
-
Well-known machinery company announced the termination of cooperation with Johnson & Johnson
Time of Update: 2021-05-02
The company's announcement pointed out that the termination of the product business with Johnson & Johnson Medical will significantly reduce operating income and net profit.
The company's announcement pointed out that the termination of the product business with Johnson & Johnson Medical will significantly reduce operating income and net profit.
-
Behind the destruction of Johnson & Johnson's vaccine: Emergent BioSolutions factory was arrested by the FDA last year
Time of Update: 2021-05-02
According to the "Washington Post" report, in April 2020, an FDA inspector found problems with training, recording, and testing procedures at Emergent BioSolutions' Bayview factory.
A spokesperson for Emergent BioSolutions said that the company will conduct'strict' quality checks throughout the vaccine production process.
-
After four price cuts, Sharp Ass finally divested its proprietary Chinese medicine business for 82 million yuan
Time of Update: 2021-05-02
This is a decrease of 58% from the initial listing price of 195 million yuan, which is a far cry from the initial investment of 481 million yuan when Sharp Aisi acquired Qiangshen Pharmaceutical.
-
Successfully promote hair regrowth!
Time of Update: 2021-05-02
Today, Eli Lilly and Incyte announced that their JAK inhibitor baricitinib has achieved positive results in the second phase 3 clinical trial BRAVE-AA1 for the treatment of patients with severe alopecia areata.
-
Johnson & Johnson abandons Erleada, Zytiga prostate cancer combination therapy regulatory application
Time of Update: 2021-05-02
After failing to reach the secondary endpoint of the key Phase III trial, Johnson & Johnson stated that it will not seek a regulatory application for the prostate cancer drug combination Erleada and Zytiga in the future.
-
Kangfang Bio-IL-4R monoclonal antibody was approved for clinical indication for moderate to severe atopic dermatitis
Time of Update: 2021-05-02
On April 8, the CDE official website showed that Kangfang Biologics Class 1 new drug AK120 injection was approved for clinical use, and the indication is moderate to severe atopic dermatitis.
AK120 is a new type of autoimmune disease treatment drug that targets IL-4R independently developed by Kangfang Biology.
-
The potential targets of Cinda’s layout, these companies are also doing
Time of Update: 2021-05-02
According to the Insight database, there is currently no CD47 monoclonal antibody approved in the world, but there are nearly 40 products in clinical research and development, and there are 3 products in the world that have progressed to the phase III clinical stage:
-
Acadi blockbuster dementia drug Nuplazid rejected by FDA
Time of Update: 2021-05-02
And Acadia pointed out that they had previously reached an agreement with the psychiatric research department supervised by Billy Dunn on the design of the drug’s key phase 3 clinical study HARMONY, which is aimed at analyzing as a single group A broad population of DRP patients.
-
Results of the first phase 3 study of the first-line immunotherapy for gastric cancer in the Chinese subgroup announced! O drug welcome progress
Time of Update: 2021-05-02
The results show that in the Chinese population, compared with chemotherapy alone, Odivo (Navulimab) combined with chemotherapy has achieved clinically significant results in the first-line treatment of unresectable advanced or metastatic gastric cancer and gastroesophageal junction cancer.
-
China National Institute of Biological Sciences of Sinopharm Group's recombinant new coronavirus vaccine approved for clinical trials
Time of Update: 2021-05-02
China Biotech stated that the genetic recombinant protein vaccine has a mature technology route and is suitable for large-scale production.
-
2020 global pharmaceutical company CEO salary competition: Johnson & Johnson approaches 200 million GSK, and Novartis heads bottom
Time of Update: 2021-05-02
The 2020 annual salary ($13 million) of the CEO of Moderna, a vaccine company that shines in the epidemic, has surpassed GSK CEO Emma Walmsley's $9.
Its income is more than twice the salary of GSK Emma Walmsley, but it is nearly $10 million less than Johnson & Johnson's Alex Gorsky.
-
Bluebird Bio launches Zynteglo in Europe blocked and starts layoffs
Time of Update: 2021-05-02
Due to the frustration of Zynteglo's listing on the first European market, Bluebird Bio is currently laying off employees and plans to "reduce and reshape" its workforce in parts of Germany.
-
Hebei Renhe Yikang Pharmaceutical Sodium Valproate Injection Enters the Administrative Approval Stage and Will Be Approved
Time of Update: 2021-04-27
Source: Minet database Medical Network News on March 24 Recently, Hebei Renhe Yikang Pharmaceutical entered the administrative examination and approval stage with the imitation of 3 types of sodium valproate injection, which is expected to be approved in the near future and won the first imitation in China.
